Pub Date : 2025-03-13DOI: 10.1097/YIC.0000000000000588
Alberto Raggi, Alessandro Serretti, Raffaele Ferri
Depression is a common comorbidity in Parkinson's disease (PD), significantly reducing patients' quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression in PD, analyzing their benefits, and limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), levodopa, dopaminergic agonists, and monoamine oxidase B inhibitors. Nonpharmacological strategies involve brief psychodynamic therapy, cognitive-behavioral therapy (CBT), physical exercise, phytomedicine, massage therapy, music therapy, phototherapy, yoga, repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation, electroconvulsive therapy (ECT), and deep brain stimulation. SSRIs, SNRIs, and some dopamine agonists have shown effectiveness and good tolerability, especially when combined with CBT or rTMS. For severe or refractory cases, ECT remains a viable option. Although many of these therapies show promise, the limited number and scale of studies for each treatment restrict the strength of current evidence. Further large-scale, multicenter randomized-controlled trials are essential to validate these preliminary findings and establish evidence-based guidelines. In addition, the potential benefits of social support and brief psychodynamic therapy in the context of PD-related depression require further exploration to provide holistic care strategies for this population.
{"title":"Treatment options for depression in Parkinson's disease: a mini-review.","authors":"Alberto Raggi, Alessandro Serretti, Raffaele Ferri","doi":"10.1097/YIC.0000000000000588","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000588","url":null,"abstract":"<p><p>Depression is a common comorbidity in Parkinson's disease (PD), significantly reducing patients' quality of life. This mini-review examines pharmacological and nonpharmacological therapies for managing depression in PD, analyzing their benefits, and limitations. Pharmacological options include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), levodopa, dopaminergic agonists, and monoamine oxidase B inhibitors. Nonpharmacological strategies involve brief psychodynamic therapy, cognitive-behavioral therapy (CBT), physical exercise, phytomedicine, massage therapy, music therapy, phototherapy, yoga, repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation, electroconvulsive therapy (ECT), and deep brain stimulation. SSRIs, SNRIs, and some dopamine agonists have shown effectiveness and good tolerability, especially when combined with CBT or rTMS. For severe or refractory cases, ECT remains a viable option. Although many of these therapies show promise, the limited number and scale of studies for each treatment restrict the strength of current evidence. Further large-scale, multicenter randomized-controlled trials are essential to validate these preliminary findings and establish evidence-based guidelines. In addition, the potential benefits of social support and brief psychodynamic therapy in the context of PD-related depression require further exploration to provide holistic care strategies for this population.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-07DOI: 10.1097/YIC.0000000000000586
Enrico Capuzzi, Massimiliano Buoli, Francesco Butturini, Nadia Bolognini, Massimo Clerici
There is a growing concern about the inappropriate use of prescription drugs in correctional facilities because of the impact on mental and physical health, drug interactions, risk of overdoses, and drug-related deaths. This study systematically examines the prevalence of abuse and misuse of prescription medications in correctional facilities and factors associated among adult individuals who are incarcerated. A systematic search was performed including articles in English, up to 31 August 2024. Fourteen relevant studies were included. The most reported prescription drugs in custodial settings were opioid substitution treatments, opioid and non-opioid analgesics, and gabapentinoids. Inappropriate use of benzodiazepines resulted also to be relevant. Inconsistency in the definition of abuse and misuse as well as the important heterogeneity in population characteristics and study designs prevent us to draw definitive conclusions as regards the prevalence of abuse and misuse of prescription treatments in custodial settings. Few and inconsistent correlations emerged from available literature. Monitoring inappropriate use of prescription medicines in correctional facilities is warranted. In particular, institutions, policy-makers, and healthcare professionals should jointly provide appropriate intervention strategies. Future research should be taken into account the important limitations of the existing literature.
{"title":"Prevalence and correlates of prescription drug abuse and misuse among adult prisoners: a systematic review.","authors":"Enrico Capuzzi, Massimiliano Buoli, Francesco Butturini, Nadia Bolognini, Massimo Clerici","doi":"10.1097/YIC.0000000000000586","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000586","url":null,"abstract":"<p><p>There is a growing concern about the inappropriate use of prescription drugs in correctional facilities because of the impact on mental and physical health, drug interactions, risk of overdoses, and drug-related deaths. This study systematically examines the prevalence of abuse and misuse of prescription medications in correctional facilities and factors associated among adult individuals who are incarcerated. A systematic search was performed including articles in English, up to 31 August 2024. Fourteen relevant studies were included. The most reported prescription drugs in custodial settings were opioid substitution treatments, opioid and non-opioid analgesics, and gabapentinoids. Inappropriate use of benzodiazepines resulted also to be relevant. Inconsistency in the definition of abuse and misuse as well as the important heterogeneity in population characteristics and study designs prevent us to draw definitive conclusions as regards the prevalence of abuse and misuse of prescription treatments in custodial settings. Few and inconsistent correlations emerged from available literature. Monitoring inappropriate use of prescription medicines in correctional facilities is warranted. In particular, institutions, policy-makers, and healthcare professionals should jointly provide appropriate intervention strategies. Future research should be taken into account the important limitations of the existing literature.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.1,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143604813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Comorbid diabetes mellitus in patients with bipolar disorder may contribute to increased morbidity and mortality. To determine the prevalence of diabetes mellitus in bipolar disorder patients and its clinico-demographic and homocysteine correlates, we conducted a cross-sectional survey of 195 bipolar disorder inpatients. They received questionnaires, clinical measurements and laboratory tests to assess demographic characteristics, anthropometric variables, clinical variables and plasma homocysteine levels. The prevalence of diabetes mellitus (including type 1, type 2 and special types) in Chinese bipolar disorder patients was 14.9%. Analysis of variance or chi-square test showed that compared with non-diabetic bipolar disorder patients, diabetic bipolar disorder patients were older, more often married, had a longer duration of disease, took less olanzapine and had a higher frequency of hypertension. However, there were no significant differences in body mass index (BMI) and homocysteine levels between diabetic and non-diabetic bipolar disorder patients. Logistic regression analysis showed that marital status and duration of disease were independently associated with diabetes mellitus in patients with bipolar disorder after controlling for age, use of olanzapine, presence of hypertension, BMI and homocysteine levels. These findings shed light on the clinico-demographic correlates of the increased prevalence of diabetes mellitus in bipolar disorder patients, rather than the correlation with some metabolic risk factors.
{"title":"Diabetes mellitus in patients with chronic bipolar disorder: prevalence, clinical correlates and relationship with homocysteine.","authors":"Li Mu, Dachun Chen, Meihong Xiu, Huixia Zhou, Dongmei Wang, Xiang-Yang Zhang","doi":"10.1097/YIC.0000000000000504","DOIUrl":"10.1097/YIC.0000000000000504","url":null,"abstract":"<p><p>Comorbid diabetes mellitus in patients with bipolar disorder may contribute to increased morbidity and mortality. To determine the prevalence of diabetes mellitus in bipolar disorder patients and its clinico-demographic and homocysteine correlates, we conducted a cross-sectional survey of 195 bipolar disorder inpatients. They received questionnaires, clinical measurements and laboratory tests to assess demographic characteristics, anthropometric variables, clinical variables and plasma homocysteine levels. The prevalence of diabetes mellitus (including type 1, type 2 and special types) in Chinese bipolar disorder patients was 14.9%. Analysis of variance or chi-square test showed that compared with non-diabetic bipolar disorder patients, diabetic bipolar disorder patients were older, more often married, had a longer duration of disease, took less olanzapine and had a higher frequency of hypertension. However, there were no significant differences in body mass index (BMI) and homocysteine levels between diabetic and non-diabetic bipolar disorder patients. Logistic regression analysis showed that marital status and duration of disease were independently associated with diabetes mellitus in patients with bipolar disorder after controlling for age, use of olanzapine, presence of hypertension, BMI and homocysteine levels. These findings shed light on the clinico-demographic correlates of the increased prevalence of diabetes mellitus in bipolar disorder patients, rather than the correlation with some metabolic risk factors.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"40 2","pages":"84-90"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143070863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2023-11-20DOI: 10.1097/YIC.0000000000000498
Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso
Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of these scales and test their psychometric characteristics. One hundred sixteen participants were recruited from Cannabis Social Clubs (CSC) in Barcelona, Spain. Participants under the effects of their own cannabis completed the Cannabis Experience Questionnaire-modified version (CEQ-mv), Addiction Research Centre Inventory-18 (ARCI-18), Psychotomimetic States Inventory (PSI) and Visual Analogue Scales (VAS). Questionnaires were completed in the CSC, providing a naturalistic setting for the study. Exploratory factor analysis and internal consistency were analyzed. PSI was reduced from a 6-factor to a 4-factor model with adequate to low reliability, ARCI-18 was reduced from a 3-factor to a 2-factor model with good reliability, and VAS were reduced from a 4-factor to a 3-factor model, also with good reliability. These questionnaires showed adequate reliability and can be used in future studies to test the subjective effects of cannabis in clinical and naturalistic settings.
{"title":"Spanish versions and validation of a series of rating scales and visual analogue scales to assess the subjective effects of cannabis.","authors":"Alberto Sainz-Cort, Marta Martín-Islas, Genís Oña, Daniel Jimenez-Garrido, Miriam López-Navarro, Elena Muñoz-Marron, Raquel Viejo-Sobera, Jose Carlos Bouso","doi":"10.1097/YIC.0000000000000498","DOIUrl":"10.1097/YIC.0000000000000498","url":null,"abstract":"<p><p>Cannabis is being legalized for medical and recreational purposes all around the world. However, the understanding of the psychological effects of cannabis is still limited, and it has been previously linked to mental disorders such as schizophrenia. Lately, new scales have been created and adapted to measure its psychological effects. The aim of this study is to create Spanish versions of some of these scales and test their psychometric characteristics. One hundred sixteen participants were recruited from Cannabis Social Clubs (CSC) in Barcelona, Spain. Participants under the effects of their own cannabis completed the Cannabis Experience Questionnaire-modified version (CEQ-mv), Addiction Research Centre Inventory-18 (ARCI-18), Psychotomimetic States Inventory (PSI) and Visual Analogue Scales (VAS). Questionnaires were completed in the CSC, providing a naturalistic setting for the study. Exploratory factor analysis and internal consistency were analyzed. PSI was reduced from a 6-factor to a 4-factor model with adequate to low reliability, ARCI-18 was reduced from a 3-factor to a 2-factor model with good reliability, and VAS were reduced from a 4-factor to a 3-factor model, also with good reliability. These questionnaires showed adequate reliability and can be used in future studies to test the subjective effects of cannabis in clinical and naturalistic settings.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"91-99"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138046808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-06-28DOI: 10.1097/YIC.0000000000000544
Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso
Objective: While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition.
Methods: In total 116 participants from a Cannabis Social Club (CSC) completed the MET and the reading the mind in the eyes test (RMET) under the effects of cannabis and were compared to 86 university students (control group). Internal consistency and convergent validity were assessed. Cognitive empathy (CE) and emotional empathy (EE) were tested in both groups.
Results: The MET CE scale shows low internal consistency, while the EE scale shows high internal consistency. Items showed similar difficulty for both groups. Cannabis users showed deficient overall emotional recognition, with reduced scores associated with positive stimuli. Overall scores for EE were similar for both groups, but the experimental group scored lower with negative stimuli when compared to controls.
Conclusion: This study validates the MET Spanish version for its use in future studies. Results confirmed deficient emotional recognition in cannabis users and a dampened reaction to negative stimuli for the first time.
目的:虽然多种精神疾病都显示社交认知能力受损,但大麻对社交认知能力的影响仍不明确。以往的研究使用多方面移情测试(MET)来研究社会认知。本研究旨在测试 MET 西班牙语版本的有效性,并评估吸食大麻对社会认知的影响:共有 116 名来自大麻社交俱乐部(CSC)的参与者在大麻作用下完成了 MET 和读心术测试(RMET),并与 86 名大学生(对照组)进行了比较。对内部一致性和收敛有效性进行了评估。对两组学生的认知移情(CE)和情感移情(EE)进行了测试:结果:MET CE 量表的内部一致性较低,而 EE 量表的内部一致性较高。两组的项目难度相似。大麻使用者的总体情绪识别能力不足,与积极刺激相关的得分降低。两组的 EE 总分相似,但与对照组相比,实验组对负面刺激的得分较低:本研究验证了 MET 西班牙语版本在未来研究中的应用。研究结果首次证实了大麻使用者的情绪识别能力不足以及对负面刺激的反应减弱。
{"title":"Validation of the Spanish version of the multifaceted empathy test: comparison between cannabis use effects and controls in social cognition.","authors":"Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jimenez-Garrido, Miriam López-Navarro, Genís Oña, Elena Muñoz-Marron, Luis Heredia, Mercè Gil-Pérez, Margarita Torrente, Paloma Vicens, José Carlos Bouso","doi":"10.1097/YIC.0000000000000544","DOIUrl":"10.1097/YIC.0000000000000544","url":null,"abstract":"<p><strong>Objective: </strong>While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition.</p><p><strong>Methods: </strong>In total 116 participants from a Cannabis Social Club (CSC) completed the MET and the reading the mind in the eyes test (RMET) under the effects of cannabis and were compared to 86 university students (control group). Internal consistency and convergent validity were assessed. Cognitive empathy (CE) and emotional empathy (EE) were tested in both groups.</p><p><strong>Results: </strong>The MET CE scale shows low internal consistency, while the EE scale shows high internal consistency. Items showed similar difficulty for both groups. Cannabis users showed deficient overall emotional recognition, with reduced scores associated with positive stimuli. Overall scores for EE were similar for both groups, but the experimental group scored lower with negative stimuli when compared to controls.</p><p><strong>Conclusion: </strong>This study validates the MET Spanish version for its use in future studies. Results confirmed deficient emotional recognition in cannabis users and a dampened reaction to negative stimuli for the first time.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"100-109"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141456568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-05-20DOI: 10.1097/YIC.0000000000000551
Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy
This systematic literature review aimed to assess the efficacy and tolerability of agomelatine versus approved medications for the treatment of generalized anxiety disorder (GAD) in adult patients. We selected randomized controlled trials on various medications used to treat GAD in adult patients. An existing systematic literature review ( Kong et al ., 2020 ) was used to identify relevant studies published before 2020. Outcomes of remission and discontinuation due to adverse events (AEs) were analyzed, following a random-effects network meta-analysis approach. Of 25 identified studies, 20 and 22 studies were included in the network meta-analysis for studying the remission and discontinuation (due to AEs) outcomes, respectively. A statistically significant difference in the remission rate was observed between agomelatine and pregabalin [odds ratio (OR), 2.22; 95% confidence interval (CI), 1.19-4.21]. For the other comparators, the results were nonsignificant; however, all the point estimates were in favor of agomelatine. Similarly, for discontinuation because of AEs, the point estimates leaned consistently toward agomelatine suggesting its higher tolerability. The probabilities of agomelatine having the highest remission rate and lowest discontinuation (due to AEs) rate were 67% and 68%, respectively. Based on its demonstrated effectiveness and tolerability, agomelatine can be considered as a drug of choice for the treatment of GAD.
{"title":"Systematic review and network meta-analysis of agomelatine for the treatment of generalized anxiety disorder in adult patients.","authors":"Sean D Hood, Olatunji Odufowora-Sita, Jean-Baptiste Briere, Marco Lucchino, Fatma Khrouf, Elzbieta Olewinska, Paulina Pierzchala, Marwa Mezghani, Mateusz Nikodem, Pierre Lévy","doi":"10.1097/YIC.0000000000000551","DOIUrl":"10.1097/YIC.0000000000000551","url":null,"abstract":"<p><p>This systematic literature review aimed to assess the efficacy and tolerability of agomelatine versus approved medications for the treatment of generalized anxiety disorder (GAD) in adult patients. We selected randomized controlled trials on various medications used to treat GAD in adult patients. An existing systematic literature review ( Kong et al ., 2020 ) was used to identify relevant studies published before 2020. Outcomes of remission and discontinuation due to adverse events (AEs) were analyzed, following a random-effects network meta-analysis approach. Of 25 identified studies, 20 and 22 studies were included in the network meta-analysis for studying the remission and discontinuation (due to AEs) outcomes, respectively. A statistically significant difference in the remission rate was observed between agomelatine and pregabalin [odds ratio (OR), 2.22; 95% confidence interval (CI), 1.19-4.21]. For the other comparators, the results were nonsignificant; however, all the point estimates were in favor of agomelatine. Similarly, for discontinuation because of AEs, the point estimates leaned consistently toward agomelatine suggesting its higher tolerability. The probabilities of agomelatine having the highest remission rate and lowest discontinuation (due to AEs) rate were 67% and 68%, respectively. Based on its demonstrated effectiveness and tolerability, agomelatine can be considered as a drug of choice for the treatment of GAD.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"62-74"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141158576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-02-29DOI: 10.1097/YIC.0000000000000541
Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli
Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was to systematically review the literature about the effects of Pilates on depressive disorders. A bibliographic search was conducted in the main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted of articles written in English language about the effectiveness of Pilates on depressive symptoms. Most of included studies are randomized controlled trials (10 out of 12). The available literature agrees in indicating that Pilates is effective in improving depressive symptoms especially when compared to inactivity and when this practice is administered for a medium-long period (8-16 weeks). In addition, Pilates seems to have at least comparable effectiveness than aerobic exercise. Pilates can be considered a reliable complementary treatment for people with depressive disorders. These findings should be interpreted considering the different types of practice administered as well as the different duration of the programs or rating scales used to assess mood symptoms. Studies with a more homogenous design are needed to confirm and make generalizable the results presented in this review.
{"title":"Is Pilates effective in improving depressive disorders? A comprehensive overview.","authors":"Francesca Legnani, Lorenzo Tassi, Teresa Surace, Enrico Capuzzi, Alice Caldiroli, Massimo Clerici, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000541","DOIUrl":"10.1097/YIC.0000000000000541","url":null,"abstract":"<p><p>Depressive disorders are disabling conditions that account for high social costs. Pilates demonstrated to have several beneficial effects on health. Objective of this manuscript was to systematically review the literature about the effects of Pilates on depressive disorders. A bibliographic search was conducted in the main database sources (Pubmed, Medline, and Scopus). The inclusion criteria consisted of articles written in English language about the effectiveness of Pilates on depressive symptoms. Most of included studies are randomized controlled trials (10 out of 12). The available literature agrees in indicating that Pilates is effective in improving depressive symptoms especially when compared to inactivity and when this practice is administered for a medium-long period (8-16 weeks). In addition, Pilates seems to have at least comparable effectiveness than aerobic exercise. Pilates can be considered a reliable complementary treatment for people with depressive disorders. These findings should be interpreted considering the different types of practice administered as well as the different duration of the programs or rating scales used to assess mood symptoms. Studies with a more homogenous design are needed to confirm and make generalizable the results presented in this review.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"53-61"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11781551/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139566260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2025-01-29DOI: 10.1097/YIC.0000000000000561
Jeroen De Troij, Chris Bervoets
This study evaluates the impact of neuroscience-based nomenclature (NbN) training on psychiatric residents in Flanders, Belgium. Addressing Zemach et al.'s findings on NbN's potential, we investigated its application in clinical practice. We assessed changes in knowledge, prescribing habits, and communication skills through focus groups and a longitudinal survey. Our results indicated no statistically significant shifts post-training, highlighting the complexity of integrating NbN into clinical practice. These findings underscore the critical need for psychopharmacological nomenclature and psychopathology to evolve in tandem, ensuring that advancements in understanding mental disorders align with pharmacological education.
{"title":"Points regarding neuroscience-based nomenclature: evaluating its impact on psychiatric residency training.","authors":"Jeroen De Troij, Chris Bervoets","doi":"10.1097/YIC.0000000000000561","DOIUrl":"https://doi.org/10.1097/YIC.0000000000000561","url":null,"abstract":"<p><p>This study evaluates the impact of neuroscience-based nomenclature (NbN) training on psychiatric residents in Flanders, Belgium. Addressing Zemach et al.'s findings on NbN's potential, we investigated its application in clinical practice. We assessed changes in knowledge, prescribing habits, and communication skills through focus groups and a longitudinal survey. Our results indicated no statistically significant shifts post-training, highlighting the complexity of integrating NbN into clinical practice. These findings underscore the critical need for psychopharmacological nomenclature and psychopathology to evolve in tandem, ensuring that advancements in understanding mental disorders align with pharmacological education.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":"40 2","pages":"119-122"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143065446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-03-01Epub Date: 2024-05-10DOI: 10.1097/YIC.0000000000000552
Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli
A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs. By inhibiting motor hyperactivity, daridorexant may reduce excessive physical exercise in individuals with anorexia nervosa (AN) restricting type. Additionally, the compound may exert anti-binge effects, suggesting broad applicability in binge ED, bulimia nervosa, and binge/purging AN. In this framework, daridorexant emerges as a promising therapeutic option, offering a multifaceted approach to improving circadian rhythms, energy balance, and overall quality of life in individuals with diverse ED subtypes.
睡眠与饮食习惯之间存在着强烈的相互作用,睡眠障碍已多次被记录在饮食失调(ED)患者的病例中。奥曲肽系统与睡眠调节、能量平衡和食物奖赏有关,它可能是睡眠改变与饮食失调行为之间的机理联系。Daridorexant 是一种双重奥曲肽受体拮抗剂(DORA),最近被批准用于治疗失眠症,其疗效和耐受性均已得到证实。由于其对奥曲肽神经元的作用,该化合物是解决睡眠相关症状和肥胖症核心症状的一个令人感兴趣的选择。通过抑制运动亢进,daridorexant 可减少神经性厌食症(AN)限制型患者的过度运动。此外,该化合物还可能具有抗暴饮暴食的作用,这表明它广泛适用于暴饮暴食性厌食症、神经性贪食症和暴饮暴食/暴食性厌食症。在这一框架下,daridorexant 成为一种很有前景的治疗选择,它提供了一种多方面的方法来改善昼夜节律、能量平衡和不同 ED 亚型患者的整体生活质量。
{"title":"The potential use of daridorexant in eating disorders: beyond the treatment of insomnia?","authors":"Alice Caldiroli, Letizia M Affaticati, Enrico Capuzzi, Davide La Tegola, Fabrizia Colmegna, Massimo Clerici, Antonios Dakanalis, Massimiliano Buoli","doi":"10.1097/YIC.0000000000000552","DOIUrl":"10.1097/YIC.0000000000000552","url":null,"abstract":"<p><p>A strong interplay exists between sleep and dietary habits, and sleep disturbances have been repeatedly documented in individuals with eating disorders (EDs). The orexin system - implicated in sleep regulation, energy homeostasis, and food reward - may represent a mechanist link between sleep alterations and disordered eating behaviors. Daridorexant is a dual orexin receptor antagonist (DORA) recently approved for the treatment of insomnia, with demonstrated efficacy and tolerability. Owing to its action on orexin neurons, the compound represents an intriguing option for addressing both sleep-related and core symptoms of EDs. By inhibiting motor hyperactivity, daridorexant may reduce excessive physical exercise in individuals with anorexia nervosa (AN) restricting type. Additionally, the compound may exert anti-binge effects, suggesting broad applicability in binge ED, bulimia nervosa, and binge/purging AN. In this framework, daridorexant emerges as a promising therapeutic option, offering a multifaceted approach to improving circadian rhythms, energy balance, and overall quality of life in individuals with diverse ED subtypes.</p>","PeriodicalId":13698,"journal":{"name":"International Clinical Psychopharmacology","volume":" ","pages":"115-118"},"PeriodicalIF":2.1,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}